For filings with the FCA include the annex
For filings with issuer exclude the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer of existing shares The Biotech Growth
to which voting rights are attached:ii Trust PLC
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights Yes
An acquisition or disposal of qualifying financial instruments which may result No
in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to No
qualifying financial instruments
An event changing the breakdown of voting rights No
Other (please specify): No
3. Full name of person(s) subject to the notification Reliance Mutual Insurance
obligation:iii Society Limited
4. Full name of shareholder(s) (if different from 3.):iv
5. Date of the transaction and date on which the threshold 24 February 2014
is crossed or reached: v
6. Date on which issuer notified: 28 February 2014
7. Threshold(s) that is/are crossed or reached: vi, vii 5%
8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of Situation previous Resulting situation after
shares to the triggering the triggering
transaction transaction
if possible using Number Number % of voting
the ISIN CODE Number of Number of rights x
of Voting of voting
Shares Rights shares rights
Direct Direct xi Indirect xii Direct Indirect
Ordinary
3,454,450 3,454,450 3,454,450 3,454,450 n/a 5.01% n/a
GB0000385517
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date xiii Conversion Period xiv rights that may be rights
acquired if the
instrument is
exercised/ converted.
C: Financial Instruments with similar economic effect to Qualifying Financial
Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial Exercise Expiration Exercise/ Number of voting % of voting
instrument price date xvii Conversion rights instrument rights xix, xx
period xviii refers to
Nominal Delta
Total (A+B+C)
Number of voting rights Percentage of voting rights
3,454,450 5.01%
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi
Proxy Voting:
10. Name of the proxy holder: n/a
11. Number of voting rights proxy holder will cease to hold: n/a
12. Date on which proxy holder will cease to hold voting rights: n/a
13. Additional information: Voting rights based on 68,886,347 shares in issue
14. Contact name: Ebru Smith
15. Contact telephone number: 01892 773 219
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.